COMPASS Pathways (CMPS) IPO Opens 38% Higher

Today's IPO for COMPASS Pathways plc (NASDAQ: CMPS) opened for trading at $23.40 after pricing 7,500,000 American Depositary Shares (“ADSs”) representing 7,500,000 ordinary shares at an initial public offering price of $17.00 per ADS.

Cowen, Evercore ISI and Berenberg are acting as joint book-running managers for the offering. Canaccord Genuity is acting as lead manager and H.C. Wainwright & Co. is acting as co-manager for the offering.

COMPASS Pathways plc is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing.

You May Also Be Interested In

• SpaceX files for 555.56M share IPO at $135/sh
• FundaMental Pharma names Dr. Hans Eriksson as chief medical officer
• Honeywell's Quantinuum raises $1.68 billion in US IPO as quantum computing heats up